Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Black Diamond Therapeutics, a precision oncology company (Nasdaq: BDTX), will participate in three investor conferences in November and December 2022. The events include the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14, the Stifel 2022 Healthcare Conference on November 15, and the Piper Sandler 34th Annual Healthcare Conference on December 1. Each presentation will be available via webcast on the company’s investor relations website for 90 days post-event.

CAMBRIDGE, Mass. and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master Key therapies, today announced that company management will participate in three upcoming investor conferences:

• The H.C. Wainwright 3^rd Annual Precision Oncology Virtual Conference. The fireside chat will take place on Monday, November 14, 2022, at 12:00 PM ET.
• The Stifel 2022 Healthcare Conference. The presentation will take place on Tuesday, November 15, 2022, at 2:25 PM ET in New York, New York.
• The Piper Sandler 34^th Annual Healthcare Conference. The presentation will take place on Thursday, December 1, 2022, at 9:30 AM ET in New York, New York.
  

A webcast of each event can be accessed by visiting the investors relations section of the Company’s website at: www.blackdiamondtherapeutics.com. A replay of the webcasts will also be available and archived on for 90 days following the events.

About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies. Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options. Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data to predict and validate oncogenic mutations that promote cancer across tumor types as MasterKey mutations. Black Diamond discovers and develops selective MasterKey therapies against these families of oncogenic mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts:
For Investors:
Julie Seidel
(212) 362-1200
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com

FAQ

What conferences will Black Diamond Therapeutics participate in November 2022?

Black Diamond Therapeutics will participate in three conferences: the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14, the Stifel 2022 Healthcare Conference on November 15, and the Piper Sandler 34th Annual Healthcare Conference on December 1.

What is the date and time for the H.C. Wainwright conference?

The H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference will take place on November 14, 2022, at 12:00 PM ET.

Where can I access the webcasts of the Black Diamond Therapeutics conferences?

Webcasts of the conferences can be accessed on the investor relations section of Black Diamond Therapeutics' website.

How long will the webcasts be available after the events?

The webcasts will be available for replay and archived for 90 days following each event.

What is the significance of Black Diamond Therapeutics in precision oncology?

Black Diamond Therapeutics focuses on developing MasterKey therapies for genetically defined cancers, addressing significant unmet needs in precision oncology.